CollPlant Biotechnologies Eyes Market with Innovative Implants

Collplant Holdings (CLGN) has released an update.

Don't Miss our Black Friday Offers:

CollPlant Biotechnologies has reported promising pre-clinical results for its innovative 3D-printed regenerative breast implants, designed to address a $3 billion market. Despite a decline in revenue, the company is actively pursuing collaborations to leverage its rhCollagen technology, aiming to enhance its financial position and advance its development programs.

For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.

Trending Articles

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.